Search Results

You are looking at 1 - 10 of 339 items for :

  • "lymphomas" x
  • All content x
Clear All

The EBV carrier state is almost general in men. The virus induces B lymphocyte proliferation in vitro, but this is counteracted in vivo by the immune response. Therefore, EBV-induced malignancies occur only when the immune response is impaired, e.g. in transplant recipients. The versatility of the viral gene expression strategy secures the consistent maintainance of the virus in healthy individuals. The viral proteins required for transformation render the cell immunogenic. Expression of the transforming genes leads to rejection, but these genes are not required for the maintenance of the viral genome. EBV is an important contributor for malignant transformation, even when it does not directly induce cell proliferation. Several mechanisms have been unravelled in EBV-associated tumors whereby the virus may modify the cellular phenotype and may influence the interaction of tumor cells with their microenvironment. The virus carrier state can lead to the evasion of apoptosis and can intensify the response to growth promoting signals, too.

Restricted access

Lennert, K., Feller, A. C.: Histopathology of non-Hodgkin lymphomas based upon the updated Kiel classification. Springer Verlag, Berlin, 1992, 312

Restricted access
Orvosi Hetilap
Authors: Leonóra Méhes, Béla Telek, Miklós Udvardy, Ágota Schlammadinger, and László Rejtő

Rejtő L.: Köpenysejtes lymphoma. In: Fókuszban az onkológia és az onkohematológia. Szerk.: Dank Magdolna, Demeter Judit. Medicina Könyvkiadó Rt., Budapest, 2006, 539

Restricted access
Orvosi Hetilap
Authors: Judit Müller, Zsuzsanna Molnár, Árpád Illés, Monika Csóka, Zsuzsanna Jakab, Beáta Deák, Tamás Schneider, Erika Várady, András Rosta, Zsófia Simon, Katalin Keresztes, Lajos Gergely, and Gábor Kovács

Tubiana, M., Henry-Amar, M., Carde, P. és mtsai: Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood, 1989

Restricted access
Orvosi Hetilap
Authors: Zsófia Miltényi, Zsófia Simon, Edit Páyer, László Váróczy, Lajos Gergely, and Árpád Illés

patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood, 1989, 73 , 47–56. Carde P. Toward comprehensive

Restricted access

. Orvostovábbképző Szemle, októberi különszám, 2004, 5–8. Armitage, J. O., Mauch, P. M., Harris, N. L. és mtsai: Diffuse large B-cell lymphoma. In Non-Hodgkin’s lymphomas. Szerk.: Mauch, P. M. és mtsai. Lippincott

Open access
Acta Veterinaria Hungarica
Authors: Urszula Jankowska, Dariusz Jagielski, Michał Czopowicz, and Rafał Sapierzyński

, R. and Marconato , L. ( 2013 ): Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation . Vet. Comp. Oncol. 13 , 348 – 362 . Avery , P. R

Restricted access
Magyar Sebészet
Authors: Ali Alzubi, István Zöllei, László Krenács, Katalin Intzédy, and János Hudák

DH Wright 1995 HLA-DRB, -DQA and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy Hum

Restricted access
Orvosi Hetilap
Authors: Péter Rajnics, László Krenács, András Kenéz, Zoltán Járay, Enikő Bagdi, and Judit Demeter

Cheung, M. M. C., Chan, J. K. C., Lau, W. H. és mtsai: Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome of 113 patients. J

Restricted access
Orvosi Hetilap
Authors: Balázs Kollár, Péter Rajnics, Béla Hunyady, Erika Zeleznik, János Jakucs, and Miklós Egyed

Gurney, K. A., Cartwright, R. A.: Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales. Hematol. J., 2002, 3 , 95

Restricted access